Bosutinib-d8 (Synonyms: SKI-606 D8) |
| Katalog-Nr.GC40080 |
Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively). It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others. Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM. It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *